Diagnostic and therapeutic advances in human growth hormone HGH insensitivity.
David A - Endocrinol Metab Clin North Am - 01-SEP-2005; 34(3): 581-95, viii
From NIH/NLM MEDLINE
NLM Citation ID:
16085161 (PubMed)
Full Source Title:
Endocrinology and Metabolism Clinics of North America
Publication Type:
Journal Article; Review; Review, Tutorial
Language:
English
Author Affiliation:
Molecular Endocrinology Centre, William Harvey Research Institute, St. Bartholomew's Hospital, London, UK.
Authors:
David A; Metherell LA; Clark AJ; Camacho-Hübner C; Savage MO
Number of References:
84
Abstract:
Diagnostic and therapeutic advances in human growth hormone insensitivity (HGH-I) have occurred principally in two areas: the molecular characterization of patients with HGH-I and treatment with recombinant human insulin like growth factor-I (IGF-I). This article discusses the current status of molecular diagnosis across the spectrum of the disorder. Treatment with recombinant human IGF-I in classical cases is summarized, and potential new targets for treatment are discussed together with the potential for therapy using the newly developed compound recombinant human IGF-I/IGF binding protein-3.
Major Subjects:
- Laron Syndrome / * diagnosis / * drug therapy / etiology / genetics
Additional Subjects:
- Drug Therapy, Combination
- Humans
- Insulin-Like Growth Factor Binding Protein 3 / therapeutic use
- Insulin-Like Growth Factor I / therapeutic use
- Mutation
- Receptors, Somatotropin / chemistry / genetics / metabolism
- Recombinant Proteins / therapeutic use
Chemical Compound Name:
(Insulin-Like Growth Factor Binding Protein 3); (Receptors, Somatotropin); (Recombinant Proteins); 67763-96-6(Insulin-Like Growth Factor I)